

1 **Title: The effect of job strain and worksite social support on reported side effects of**
2 **COVID-19 vaccine: a prospective study of employees in Japan**

3 Running title: JOB STRESS AND SIDE EFFECTS OF VACCINE

4

5 Authors.

6 Natsu Sasaki (MD)¹, nasasaki-ky@umin.ac.jp

7 Reiko Kuroda (MD, Ph.D.)², urk@ohs.adm.u-tokyo.ac.jp

8 Kanami Tsuno (Ph.D.)³, ktsuno-ky@umin.ac.jp

9 Kotaro Imamura (Ph.D.)¹, kouima-ky@umin.ac.jp

10 Norito Kawakami (MD, PhD)¹, nkawakami@m.u-tokyo.ac.jp

11

12 ¹ Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Tokyo,
13 Japan

14 ² Division for Environment, Health, and Safety, The University of Tokyo, Tokyo, Japan

15 ³ School of Health Innovation, Kanagawa University of Human Services, Kanagawa, Japan

16

17

18

19 Corresponding author: **Norito Kawakami (MD)**

20 Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Tokyo,
21 Japan

22 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan

23 E-mail: nkawakami@m.u-tokyo.ac.jp

24 Telephone: +81-3-5841-3364, Fax: +81-3-5841-3392

25

26 **DISCLOSURE**

27 **Approval of the research protocol:** The Research Ethics Committee of the Graduate School of
28 Medicine/Faculty of Medicine, The University of Tokyo, approved this study, No.
29 10856-(2)(3)(4)(5).

30

31 **Informed consent:** Online informed consent was obtained from all participants after full
32 disclosure and explanation of the purpose and procedures of this study. We explained that their
33 participation was voluntary, and they could withdraw consent for any reason simply by not
34 completing the questionnaire.

35

36 **Registry and registration number of the study/trial:** N/A.

37

38 **Animal studies:** N/A.

39

40 **Conflict of interest:** NK received grants from SB AtWork Corp, Fujitsu Ltd, and TAK Ltd,
41 personal fees from the Occupational Health Foundation, SB AtWork Corp, RIKEN, Japan
42 Aerospace Exploration Agency (JAXA), Japan Dental Association, Sekisui Chemicals, Junpukai
43 Health Care Center, Osaka Chamber of Commerce and Industry, outside the submitted work.
44 RK received grants from Grant-in-Aid for Young Scientists (B) from Japan Society for the
45 Promotion of Science (JSPS), personal fees from SATORI electric CO., LTD, NXP
46 Semiconductors, RIKEN, Toyotsu Chemiplas, Mitsubishi Materials Corporation outside the
47 submitted work."

48

49 **Funding/Support:** The 2021 Health, Labour and Welfare Policy Research Grants; The Japan
50 Ministry of Health, Labour, and Welfare; and an internal fund of the Department of
51 Mental Health, Graduate School of Medicine at the University of Tokyo, supported
52 this work.

53

54 **Role of the Funder/Sponsor:** The sponsors had no role in the design and procedures of the
55 study; collection, management, analysis, and interpretation of the data; the preparation, review,
56 or approval of the manuscript; and the decision to submit the manuscript for publication.

57

58 **Author contribution:** NK oversaw this study, supervising the process and providing his expert
59 opinion. NS and NK organized the study design and analyzed the data. Collaborators RK, KT,
60 and KI ensured that questions related to the accuracy or integrity of any part of the work were
61 appropriately investigated and resolved. All authors participated in administering the survey. NS

62 and NK wrote the first draft of the manuscript, and all other authors critically revised it. All
63 authors approved the final version of the manuscript.

64

65 **Data availability statement:** The data supporting this study's findings are available from the
66 corresponding author, NK, upon reasonable request.

67

68 **Abstract (268 words)**

69 **Objectives:** This prospective study aimed to examine the association of job demands, job control,
70 and the lack of supervisor and coworker support with side effects after receiving COVID-19
71 vaccination in a sample of employees in Japan.

72 **Methods:** The data were retrieved from an online panel of full-time employees (E- COCO- J).
73 The analysis included participants who were employed and were not vaccinated at baseline (June
74 2021) but received vaccination at a four-month follow-up (October 2021). An 11-item scale
75 measured the side effects of COVID-19 vaccines. Four types of psychosocial working conditions
76 (i.e., job demands, job control, and supervisor and coworker support) were measured using the
77 Brief Job Stress Questionnaire (BJSQ). Multiple linear regression analyses were conducted to
78 examine the relationship between the psychosocial working conditions and side effects of
79 COVID-19 vaccines, adjusting for gender, age, educational attainment, marital status, occupation,
80 chronic disease, dose of vaccination, anxiety from potential side effects of vaccines, fear and
81 worry about COVID-19, and psychological distress at baseline.

82 **Results:** Overall, 747 employees were included in the analysis. The average number of side
83 effects was 3.78 (SD=2.19): Arm pain (81.1%), fatigues (64.1%), muscle pains (63.3%), and
84 fever (37.5 degrees Celsius +) (53.5%) were reported more frequently. Coworker support score
85 was significantly and negatively associated with the numbers of side effects (standardized
86 $\beta=-0.122$, $p=0.017$). Women, young age, second time vaccination, and high psychological
87 distress were significantly associated with several side effects.

88 **Conclusions:** Employees with low coworker support may be more likely to have side effects after
89 COVID-19 vaccinations. The findings of this study could inform employees with low coworker
90 support that increasing workplace support may reduce the side effects.

91

92 **Keywords:** reactogenicity, side reactions, job stressors, mental health, occupational health

93

94 **Highlights**

95 ☐ The effect of poor psychosocial working conditions on side effects after COVID-19
96 vaccinations was unknown.

97 ☐ Poor coworker support at baseline was significantly associated with increased side effects
98 after COVID-19 vaccinations.

99 ☐ Informing workers with low coworker support about the findings may help them prepare for
100 the side effect and motivate them to improve coworker support to reduce side effects.

101

102 **Manuscript**

103 **Introduction**

104 Solicited local and systemic adverse events, that is, side effects after the injection of
105 COVID-19 vaccines, have been frequently reported [1, 2]. They affect the daily life activities of
106 the recipients. They may also be a major reason for vaccine hesitancy [3]. The immediate and
107 non-specific innate immune response can produce various side effects [4]. Women, young
108 people, second dose, heterologous prime-boost, and individuals with previous SARS-CoV-2
109 infection are more likely to experience side effects of the COVID-19 vaccine [5, 6]. Differences
110 in side effects have been attributed to increased immunogenicity to the COVID-19 vaccine
111 among these groups [5,7,8].

112 Psychological factors can affect the immune system's response to the vaccine, thus the
113 side effect [4]. After influenza virus vaccination, for example, chronic depression was
114 associated with excessive and prolonged inflammatory responses [7]. Exposures to a brief
115 stressor before receiving the typhoid vaccine amplified the inflammatory response to the
116 vaccine [8]. Psychological factors may also trigger short-term side effects of COVID-19
117 vaccination. However, to date, no study has examined this association.

118 Poor psychosocial working conditions, such as high job demands, low job control [9, 10],
119 and lack of workplace support [11], have been associated with immune system dysregulation
120 [12-15]. Poor psychosocial working conditions often increase inflammatory markers while
121 reducing cellular immune functions (such as NK cell activity, NK and T cell subsets,
122 CD4+/CD8+ ratio) [16]. Thus, people working under poor psychosocial conditions may
123 experience more side effects after the COVID-19 vaccine because of decreased innate immune
124 response to vaccination caused by such stressful conditions.

125 This prospective study aimed to examine the association of job demands, job control, and

126 lack of workplace support with side effects after receiving COVID-19 vaccination in a sample
127 of full-time employees in Japan.

128

129 **Methods**

130 **Study design and participants**

131 The data were collected as a part of a large-scale prospective panel study, the Employee Cohort
132 Study in the Covid-19 pandemic in Japan (E- COCO- J) [17, 18], targeting a sample of full-time
133 employees recruited from the panel of the Japanese internet company in March 2020 (N=1448).
134 After completing six surveys (including the first survey) between March 2020 and March 2021,
135 the seventh and eighth surveys were administered in June and October 2021, respectively. In
136 this prospective study, the baseline variables (such as job strain and workplace support) were
137 measured in the seventh survey (hereafter called the baseline), and the outcome variables (i.e.,
138 the side effect of the COVID-19 vaccine) were measured in the eighth survey (hereafter called
139 as the follow-up). The participants' eligibility criteria were: 1) being employed at baseline, 2)
140 not being vaccinated at baseline, and 3) being vaccinated at follow-up. The details of the
141 recruitment process are shown in **Figure 1**.

142 The Research Ethics Committee of the Graduate School of Medicine/Faculty of Medicine,
143 The University of Tokyo, approved this study, No. 10856-(2)(3)(4)(5).

144

145 **Measurement variables**

146 *Side effects of COVID-19 vaccine*

147 A list of 11 side effects of the COVID-19 vaccine was created by referring to the report of the
148 possible common side effects reported by the Centers for Disease Control and Prevention
149 (CDC) [19], including arm pain/redness/swelling, fatigues/tiredness, headache, muscle

150 pain/joint pain, chills, fevers (37.5 degree+), nausea/vomit, diarrhea, lymph node pain, severe
151 reactions to being needed medical care (e.g., anaphylaxes), and delayed local arm reactions after
152 7 days of vaccinations (i.e., COVID arm). We developed an 11-item scale of side effects of
153 COVID-19 vaccines. Participants were asked whether they had each of the listed side effects
154 within a few days after the vaccination: “Did you experience any of the following side effects
155 within 1 to 3 days after getting a COVID-19 vaccine?” If respondents received only the first
156 dose, they were asked to report their experience at that time; if they received the vaccination
157 twice, they were asked to report their experience when their symptoms were most severe. The
158 response options were Yes or No. The total number of side effects, ranging from 0 to 11, was
159 used as a primary outcome.

160

161 *Psychosocial working conditions*

162 Psychosocial working conditions were assessed based on the job-demand-control (JDC) model
163 and the job-demand-control-support (JDCS) model, which explain the occurrence of mental
164 strain in a workplace context [9, 20]. Four components of the JDC/JDCS model, job demand
165 (quantitative job overload), job control, coworker support, and supervisor support, were
166 measured using the corresponding subscales of the Brief Job Stress Questionnaire (BJSQ) [21].
167 Each scale comprised three items, with each being rated on a 4-point Likert-type scale from
168 ‘very much so’ = 1 to ‘not at all’ = 4 for job demands and job control and from ‘Extremely’ = 4
169 to ‘not at all’ = 1) for supervisor and coworker support. Total scores for each subscale ranged
170 from 3 to 12, with a higher score indicating the higher degree of the corresponding component.
171 The four components of the BJSQ showed good reliability and validity.

172

173 *Covariates*

174 *Anxiety about side effects of vaccines*

175 One original item was used to assess anxiety about the side effects of vaccines. This item stated,
176 “I am concerned about the effectiveness and side effects of COVID-19 vaccines,” Responses
177 were scored on a 4-point Likert-type scale (ranging from 1 “Not at all” to 4 “Feel strong”). The
178 reliability and validity were not examined.

179

180 *Fear and worry about COVID-19*

181 One original item was used to assess participants’ fear of COVID-19. The item asked, “Do you
182 feel anxious about COVID-19?” Responses were scored on a 6-point Likert-type scale (ranging
183 from 1 “Not at all” to 6 “Feel strongly”). The reliability and validity were not examined, but
184 several papers using the same scale were published [17, 22, 23].

185

186 *Psychological distress*

187 Psychological distress was measured using K6 (Kessler 6) [24, 25]. Respondents were asked to
188 report how frequently in the past 4 weeks they felt nervous, hopeless, restless or fidgety,
189 worthless, depressed, and that everything was an effort. The response options were “none of the
190 time”=0, “a little of the time”=1, “some of the time”=2, “most of the time”=3, or “all of the
191 time”=4. The total score ranges from 0 to 24. The Japanese version of K6 showed good
192 reliability and validity [26]. K6 performs just as well as the Composite International Diagnostic
193 Interview (CIDI) Short Form in identifying individuals with clinically significant mental
194 disorders [27].

195

196 *Demographic variables*

197 We measured gender, age, educational attainment, marital status, occupation, chronic disease at

198 baseline, and dose of vaccination at follow-up. Chronic disease was defined as having any
199 physical and psychological diseases which were currently treated in the medical settings,
200 including hypertension, diabetes, heart disease (e.g., angina, heart failure), cerebrovascular
201 disease (e.g., cerebral infarction, cerebral hemorrhage), cancer/malignant neoplasm, respiratory
202 disease, liver disease, kidney disease, and depression/anxiety/unstable moods. Hospital
203 admissions or home treatment over one week regardless of COVID-19 in the past 6 months was
204 measured at the follow-up.

205

206 **Statistical analysis**

207 The descriptive statistics were used to describe sociodemographic characteristics, psychosocial
208 working conditions, and the prevalence of reported side effects. We conducted multiple linear
209 regression analyses to examine the relationship between four psychosocial factors at work (job
210 demand, job control, coworker's support, and supervisor support) and the side effects of
211 COVID-19 vaccines in the crude model (Model 1). The relationship was also assessed when
212 adjusting for gender, age, educational attainment, marital status, occupation, chronic disease, and
213 dose of vaccination (Model 2) and for anxiety about side effects of vaccines, fear and worry about
214 COVID-19 and psychological distress at baseline (Model 3). The same subgroup analysis was
215 conducted among participants who received second vaccination.

216 The sample may have included participants who tested positive for COVID-19 before the
217 baseline or during the follow-up, which may have confounded the results. We were not allowed to
218 ask whether the participants were infected in the survey for ethical reasons. Instead, we asked
219 whether they received any in-hospital or home treatment for one week or longer in the past six
220 months to exclude respondents who were potentially infected. As a sensitivity analysis, we
221 conducted the same analysis excluding participants who reported hospital admissions or home

222 treatment for one week or longer during the past 6 months. The primary outcome was the total
223 number of side effects.

224 Multiple logistic regression analysis was conducted to examine the relationship between
225 four psychosocial factors at work and severe adverse effects requiring medical care after getting
226 vaccinated (i.e., anaphylaxis). SPSS 28.0 (IBM Corp) Japanese version was used. Statistical
227 significance was set as a two-sided $p < .05$.

228

229 **Results**

230 The participants' characteristics are shown in **Table 1**. The mean age was 44.8 years old
231 (min-max: 22-62 years old). Those with chronic disease accounted for 14.5%, and 8.6% of the
232 participants experienced hospital admissions or home treatment over one week regardless of
233 COVID-19 during the past 6 months.

234 The prevalence rates of self-reported side effects after getting a COVID-19 vaccine are
235 shown in **Table 2**. The most prevalent side effects were arm pain/redness/swelling (81.1%),
236 fatigues/tiredness (64.1%), muscle pains/joint pains (63.3%), and fever (37.5 degree Celsius +)
237 (53.5%). In contrast, severe reactions requiring needed medical care (e.g., anaphylaxes)
238 accounted for 2.9%.

239 The results of multiple linear regression analysis are shown in **Table 3**. Job demand and
240 coworker support were significantly associated with the number of side effects in Model 2
241 (standardized $\beta=0.081$, $p=0.041$; $\beta=-0.134$, $p=0.008$, respectively). Coworker support also
242 showed significance in Model 3 ($\beta=-0.122$, $p=0.017$). Psychological distress at baseline was
243 significantly associated with side effects in Model 3 ($\beta=0.150$, $p<0.001$). Women, younger age,
244 and second vaccination were significantly associated with the great number of the side effects.

245 The subgroup analysis with participants who received second vaccination (N=687)

246 showed the negative associations of coworker support with the total number of side effects in
247 Model 3 ($\beta=-0.115$, $p=0.034$) (**Appendix 1**).

248 The result of multiple linear regression analysis among those who did not experience
249 hospital admissions or home treatment during the past six months ($N=683$) is shown in **Appendix**
250 **2**. In Model 3 of the multiple linear regression analysis (**Appendix 3**), coworker support was
251 significantly negatively associated with the number of side effects ($\beta=-0.131$, $p=0.014$).

252 None of the four psychosocial working conditions correlated significantly with the
253 presence of severe adverse reactions (1 item) in the adjusted model in the entire sample ($N=747$)
254 (**Appendix 4A**) or among participants without hospital admissions/home treatment ($N=683$)
255 (**Appendix 4B**).-

256

257

258 **Discussion**

259 High coworker support was positively associated with fewer side effects after the COVID-19
260 vaccinations. Job demand, control, and supervisor support did not show significant associations.
261 However, high psychological distress was associated with side effects. This study demonstrated
262 the importance of psychosocial working conditions in employees experiencing various side
263 effects after the COVID-19 vaccinations.

264

265 Coworker support showed a significant negative association with the total number of side
266 effects of the COVID-19 vaccine. The finding is consistent with previous findings showing that
267 psychological factors, i.e., exposure to a stressor, precipitate immediate inflammatory reactions
268 to vaccines [4, 7] and that poor psychosocial working conditions often increase inflammatory
269 markers [16]. However, this association was observed even after adjusting for baseline

270 psychological distress, fear, and worry about COVID-19. Although psychological distress may
271 partially mediate the association, poor coworker support may be independently associated with
272 the side effect of the COVID-19 vaccine. The possible mechanism underlying the association is
273 unclear, but the finding that the lack of social support generally increases systematic
274 inflammations might clarify this mechanism [4, 12, 28, 29]. Mediators and products that cause
275 inflammation in the circulation can affect body systems to cause systemic side effects [30]. For
276 instance, a previous study indicated that low coworker support influenced inflammation
277 biomarkers in a group of employees who worked more than 41h per week [12]. It may be
278 plausible that elevated inflammatory responses associated with lack of coworker support may
279 exaggerate an innate immune response to the COVID-19 vaccine [31, 32].

280

281 Job demand, control, or supervisor support showed no significant associations with reported
282 side effects. However, these associations may have been underestimated due to this study's
283 relatively small sample size. These psychosocial working conditions are also related to chronic
284 inflammations; for example, previous studies have indicated that high supervisor support was
285 associated with low inflammation markers [12, 33]. Hence, environmental factors may
286 potentially affect the experience of side effects. Future investigations should use larger samples
287 to replicate the findings.

288

289 **Strengths and limitations**

290 The strength of this study was the prospective nature of the study design. This study showed
291 direct and indirect effects of the psychosocial working conditions on the immune function.
292 However, the present study had several limitations. First, self-reported measures were used to
293 assess the psychosocial working conditions and side effects. People with poor working

294 conditions or high distress may have overreported the side effects. Besides, employees with low
295 coworker support may be easily conscious of side effects because fewer people around them
296 take over their work, so they are more concerned about the impact on their work. Second, this
297 study did not consider other psychosocial conditions other than job demand, job control, and
298 workplace social support. Other factors should be investigated in future research. Third,
299 generalizability was limited because the participants were full-time employees in Japan, and the
300 data were retrieved from the online panel. Fourth, the significant association found in this study
301 could have been superficial, as other potential confounding factors could have affected the
302 results. Fifth, this study addressed only a very short-term innate immune response to vaccination
303 but did not examine the effects on cellular or humoral immunity after vaccination and over
304 longer period. The previous meta-analysis revealed a negative association between stress and
305 antibody production after influenza vaccinations [34]. In addition, several studies have
306 suggested that lonely or socially isolated individuals had a weak immune response after
307 vaccinations [4, 35, 36] and increased susceptibility to infectious disease [37]. Future studies
308 can examine the association of psychosocial working conditions and psychological stress with
309 decreased responses to vaccinations and infectious susceptibility.

310

311 **Implications for future practice**

312 This study demonstrated the importance of psychosocial working conditions, especially
313 coworker support, in experiencing certain adverse events after the COVID-19 vaccinations.
314 Informing employees about the potential effects of low coworker support on adverse vaccine
315 outcomes may help them prepare for these side effects. Improving coworker support in the
316 workplace may reduce some of the reported side effects. Active actions to control the
317 reactogenicity may ease the vaccine hesitancy. Even before COVID-19, stressors and stress

318 reactions have been known to be important factors in immune functions. Accordingly, they
319 should receive even greater attention during the pandemic. Further studies are needed to
320 examine the association of social supports with immune responses.

321

322 **Conclusions**

323 Coworker support showed a significantly negative association with experiencing short-term side
324 effects. Providing information about the findings may help employees cope and prepare for
325 potential side effects. Future research is needed to replicate the findings with large sample size.

326

327 **Acknowledgment**

328 We appreciate the involvement of all E-COCO-J study participants and collaborators.

329

330 **References**

- 331 1. Chapin-Bardales, J., J. Gee, and T. Myers, *Reactogenicity Following Receipt of*
332 *mRNA-Based COVID-19 Vaccines*. JAMA, 2021. **325**(21): p. 2201-2202.
- 333 2. Baden, L. R., et al., *Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine*. N
334 Engl J Med, 2021. **384**(5): p. 403-416.
- 335 3. Biswas, M. R., et al., *A Scoping Review to Find Out Worldwide COVID-19 Vaccine*
336 *Hesitancy and Its Underlying Determinants*. Vaccines (Basel), 2021. **9**(11).
- 337 4. Madison, A. A., et al., *Psychological and Behavioral Predictors of Vaccine*
338 *Efficacy: Considerations for COVID-19*. Perspect Psychol Sci, 2021. **16**(2): p.
339 191-203.
- 340 5. Menni, C., et al., *Vaccine side-effects and SARS-CoV-2 infection after vaccination*
341 *in users of the COVID Symptom Study app in the UK: a prospective observational*
342 *study*. Lancet Infect Dis, 2021. **21**(7): p. 939-949.
- 343 6. Saita, M., et al., *Reactogenicity following two doses of the BNT162b2 mRNA COVID-19*
344 *vaccine: Real-world evidence from healthcare workers in Japan*. Journal of
345 infection and chemotherapy: official journal of the Japan Society of Chemotherapy,
346 2022. **28**(1): p. 116-119.
- 347 7. Glaser, R. et al., *Mild depressive symptoms are associated with amplified and*
348 *prolonged inflammatory responses after influenza virus vaccination in older adults*.
349 Archives of general psychiatry, 2003. **60**(10): p. 1009-1014.

- 350 8. Brydon, L., et al., *Synergistic effects of psychological and immune stressors on*
351 *inflammatory cytokine and sickness responses in humans*. *Brain, behavior, and*
352 *immunity*, 2009. **23**(2): p. 217-224.
- 353 9. Karasek Jr, R.A., *Job demands, job decision latitude, and mental strain:*
354 *Implications for job redesign*. *Administrative science quarterly*, 1979: p. 285-308.
- 355 10. Karasek, R., & Theorell, T, *Healthy Work: Stress, Productivity, and the*
356 *Reconstruction of Working Life*. 1990, New York: Basic Books.
- 357 11. Johnson, J.V. and E.M. Hall, *Job strain, workplace social support, and*
358 *cardiovascular disease: a cross-sectional study of a random sample of the Swedish*
359 *working population*. *Am J Public Health*, 1988. **78**(10): p. 1336-42.
- 360 12. Eguchi, H., et al., *Source - specific workplace social support and high -*
361 *sensitivity C - reactive protein levels among Japanese workers: A 1 - year*
362 *prospective cohort study*. *American journal of industrial medicine*, 2016. **59**(8):
363 p. 676-684.
- 364 13. Shirom, A., et al., *The Job Demand-Control-Support Model and stress-related*
365 *low-grade inflammatory responses among healthy employees: A longitudinal study*.
366 *Work & Stress*, 2008. **22**(2): p. 138-152.
- 367 14. Nabi, H. et al., *Do psychological factors affect inflammation and incident coronary*
368 *heart disease: the Whitehall II Study*. *Arteriosclerosis, thrombosis, and vascular*
369 *biology*, 2008. **28**(7): p. 1398-1406.
- 370 15. Sara, J.D., et al., *Association Between Work&Related Stress and Coronary Heart*
371 *Disease: A Review of Prospective Studies Through the Job Strain, Effort&Reward*
372 *Balance, and Organizational Justice Models*. *Journal of the American Heart*
373 *Association*, 2018. **7**(9): p. e008073.
- 374 16. Nakata, A., *Psychosocial job stress and immunity: a systematic review*. *Methods*
375 *Mol Biol*, 2012. **934**: p. 39-75.
- 376 17. Kawakami, N. et al., *The Effects of Downloading a Government-Issued COVID-19*
377 *Contact Tracing App on Psychological Distress During the Pandemic Among Employed*
378 *Adults: Prospective Study*. *JMIR Ment Health*, 2021. **8**(1): p. e23699.
- 379 18. Sasaki, N., et al., *The deterioration of mental health among healthcare workers*
380 *during the COVID-19 outbreak: A population-based cohort study of workers in Japan*.
381 *Scand J Work Environ Health*, 2020. **46**(6): p. 639-644.
- 382 19. (CDC);, C. f. D. C. a. P. *Possible Side Effects After Getting a COVID-19 Vaccine*. 2021
383 [cited 2021 November 18]; Available from:
384 <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html>.
- 385 20. Johnson, J.V., E.M. Hall, and T. Theorell, *Combined effects of job strain and social*

- 386 *isolation on cardiovascular disease morbidity and mortality in a random sample*
387 *of the Swedish male working population.* Scand J Work Environ Health, 1989. **15**(4):
388 p. 271-9.
- 389 21. Shimomitsu, T., et al., *Investigation research report concerning prevention of*
390 *disease related to work in 1997 the Ministry of Labor: III Stress measurement*
391 *research group report.* Tokyo: Tokyo Medical University, 2000: p. 101-169.
- 392 22. Sasaki, N., et al., *Workplace responses to COVID-19 associated with mental health*
393 *and work performance of employees in Japan.* J Occup Health, 2020. **62**(1): p. e12134.
- 394 23. Sasaki, N., et al., *Exposure to media and fear and worry about COVID-19.* Psychiatry
395 Clin Neurosci, 2020. **74**(9): p. 501-502.
- 396 24. Kessler, R. C., et al., *Short screening scales to monitor population prevalences*
397 *and trends in non-specific psychological distress.* Psychol Med, 2002. **32**(6): p.
398 959-76.
- 399 25. Kessler, R. C., et al., *Screening for serious mental illness in the general*
400 *population.* Arch Gen Psychiatry, 2003. **60**(2): p. 184-9.
- 401 26. Sakurai, K., et al., *Screening performance of K6/K10 and other screening*
402 *instruments for mood and anxiety disorders in Japan.* Psychiatry Clin Neurosci,
403 2011. **65**(5): p. 434-41.
- 404 27. Kessler, R. C., et al., *Screening for Serious Mental Illness in the General*
405 *Population.* Archives of General Psychiatry, 2003. **60**(2): p. 184-189.
- 406 28. Andrew P, S., *The Psychology of the Common Cold and Influenza: Implications for*
407 *COVID-19.* International Journal of Clinical Virology, 2020. **4**(1): p. 027-031.
- 408 29. Uchino, B.N., et al., *Social support, social integration, and inflammatory*
409 *cytokines: A meta-analysis.* Health Psychology, 2018. **37**(5): p. 462.
- 410 30. Herve, C., et al., *The how's and what's of vaccine reactogenicity.* NPJ Vaccines,
411 2019. **4**: p. 39.
- 412 31. Mortensen, R. F., *C-reactive protein, inflammation, and innate immunity.* Immunol
413 Res, 2001. **24**(2): p. 163-76.
- 414 32. Tanaka, T., M. Narazaki, and T. Kishimoto, *IL-6 in inflammation, immunity, and*
415 *disease.* Cold Spring Harb Perspect Biol, 2014. **6**(10): p. a016295.
- 416 33. Nakata, A., M. Irie, and M. Takahashi, *Source-Specific Social Support and*
417 *Circulating Inflammatory Markers Among White-Collar Employees.* Annals of
418 Behavioral Medicine, 2013. **47**(3): p. 335-346.
- 419 34. Pedersen, A. F., R. Zachariae, and D. H. Bovbjerg, *Psychological stress and antibody*
420 *response to influenza vaccination: a meta-analysis.* Brain Behav Immun, 2009.
421 **23**(4): p. 427-33.

- 422 35. Glaser, R., et al., *Stress-induced modulation of the immune response to recombinant*
423 *hepatitis B vaccine*. Psychosomatic medicine, 1992. **54**(1): p. 22-29.
- 424 36. Gallagher, S. et al., *Psychosocial factors are associated with the antibody*
425 *response to both thymus-dependent and thymus-independent vaccines*. Brain,
426 behavior, and immunity, 2008. **22**(4): p. 456-460.
- 427 37. Cohen, S., et al., *Social ties and susceptibility to the common cold*. Jama, 1997.
428 **277** (24): p. 1940-1944.
429

Table 1. Participants' sociodemographic characteristics and psychosocial factors at work at baseline (N=747).

Variables [possible range]	N (%)	Mean (SD)
Age		44.79 (10.18)
20 – 29 years old	62 (8.3)	
30 – 39 years old	173 (23.2)	
40 – 49 years old	233 (31.2)	
50+	279 (37.3)	
Gender		
Men	423 (56.6)	
Women	324 (43.4)	
Marital status		
Single	320 (42.8)	
Married	427 (57.2)	
Educational attainment (a)		
Less than a high school diploma	145 (19.3)	
College/vocational	162 (16.2)	
Undergraduate	296 (39.6)	
Graduate+	37 (5.0)	
Unknown/others	148 (19.8)	
Occupation (b)		
Mangers	93 (12.4)	
Non-manual workers	447 (59.8)	
Manual workers	184 (24.6)	
Healthcare workers	23 (3.1)	
Chronic disease (c)		
None	639 (85.5)	
Any	108 (14.5)	
Hospital admissions/ home treatment (d)		
No	683 (91.4)	
Yes	64 (8.6)	
Vaccination		
First shot	60 (8.0)	
Second shot	687 (92.0)	
Anxiety about side effects of vaccination [1-4]		2.99 (0.82)
Fear and worry about COVID-19 [1-6]		4.26 (1.23)
Job demand [3-12]		7.92 (2.35)
Job control [3-12]		8.00 (2.19)
Coworker support [3-12]		6.95 (2.15)
Supervisor support [3-12]		6.65 (2.21)
Psychological distress [0-24]		5.55 (5.73)

SD: Standard deviation.

(a) Information about educational attainment was obtained in May 2020.

(b) Information about the occupation was created by merging the data obtained in February 2019 with information of the job category (i.e., healthcare workers or not) in May 2020.

(c) Chronic disease refers to having any physical and psychological diseases currently treated in the medical settings, including hypertension, diabetes, heart disease (e.g., angina, heart failure), cerebrovascular disease (e.g., cerebral infarction, cerebral hemorrhage), cancer/malignant neoplasm, respiratory disease, liver disease, kidney disease, and depression/anxiety/unstable moods.

(d) Hospital admissions or home treatment over one week, regardless of COVID-19, in the past 6 months.

Table 2. Prevalence of self-reported side effects after getting a COVID-19 vaccine.

Variables [possible range]	Entire sample (N=747)	
	N (%)	Mean (SD)
Total number of side reactions [0-11]		3.78 (2.19)
Arm pain/ redness/ swelling	606 (81.1)	
Fatigues/ tiredness	479 (64.1)	
Headache	295 (39.5)	
Muscle pains/ joint pains	473 (63.3)	
Chills	239 (32.0)	
Fever (37.5 degree+)	400 (53.5)	
Nausea/ vomit	50 (6.7)	
Diarrhea	55 (7.4)	
Lymph node pain	67 (9.0)	
Severe reactions to be needed medical care (e.g., anaphylaxes)	22 (2.9)	
Delayed local arm reactions after 7 days of vaccinations (i.e., COVID arm)	139 (18.6)	

Table 3. Association between psychosocial factors at work and the total number of side effects (a) of COVID-19 vaccines in the entire sample (N=747): Multiple linear regression analysis.

	Model 1				Model 2				Model 3			
	B	SE	β (b)	p	B	SE	β (b)	p	B	SE	β (b)	p
Job demand	0.073	0.034	0.079	0.032*	0.076	0.037	0.081	0.041*	0.044	0.038	0.046	0.251
Job control	-0.062	0.039	-0.062	0.114	-0.047	0.041	-0.048	0.249	-0.019	0.041	-0.020	0.640
Coworker support	-0.117	0.048	-0.115	0.016*	-0.136	0.051	-0.134	0.008*	-0.123	0.052	-0.122	0.017*
Supervisor support	0.054	0.049	0.055	0.264	0.042	0.050	0.043	0.406	0.058	0.050	0.060	0.246
Gender (0:men, 1:women)					0.796	0.198	0.183	<0.001*	0.729	0.201	0.167	<0.001*
Age					-0.052	0.009	-0.247	<0.001*	-0.048	0.009	-0.227	<0.001*
Education (0:less than university, 1:university+) (c)					0.222	0.188	0.051	0.237	0.218	0.186	0.050	0.241
Marital status (0: single, 1: married)					0.168	0.186	0.038	0.368	0.183	0.184	0.042	0.321
Non-manual workers (ref: managers)					-0.036	0.283	-0.008	0.898	-0.087	0.280	-0.020	0.755
Manual workers (ref: managers)					-0.139	0.323	-0.027	0.666	-0.250	0.321	-0.049	0.437
Healthcare workers (ref: managers)					0.040	0.497	0.004	0.936	-0.102	0.494	-0.009	0.837
Chronic disease					0.187	0.239	0.031	0.434	-0.019	0.241	-0.003	0.938
Vaccination (ref: first time)					1.625	0.310	0.206	<0.001*	1.630	0.308	0.207	<0.001*
Anxiety about side effects of vaccination									0.028	0.114	0.011	0.804
Fear and worry about COVID-19									0.120	0.077	0.067	0.120
Psychological distress									0.056	0.016	0.150	<0.001*

(a) Eleven side effects were reported after vaccination: arm pain/redness/swelling, fatigues/ tiredness, headache, muscle pains/joint pains, chills, fever (37.5 degree+), nausea/vomit, diarrhea, lymph node pain, severe reactions requiring medical care (e.g., anaphylaxis), and delayed local arm reactions after 7 days of vaccinations (i.e., COVID arm).

(b) Standardized beta.

(c) Educational attainment was dichotomized into two categories. Missing or unknown was classified as less than university attainment.

SE: Standard errors. *p<0.05.